237 related articles for article (PubMed ID: 24195605)
1. Biosafety considerations using gamma-retroviral vectors in gene therapy.
Deichmann A; Schmidt M
Curr Gene Ther; 2013 Dec; 13(6):469-77. PubMed ID: 24195605
[TBL] [Abstract][Full Text] [Related]
2. Biosafety of recombinant adeno-associated virus vectors.
Dismuke DJ; Tenenbaum L; Samulski RJ
Curr Gene Ther; 2013 Dec; 13(6):434-52. PubMed ID: 24195602
[TBL] [Abstract][Full Text] [Related]
3. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
4. Biosafety challenges for use of lentiviral vectors in gene therapy.
Rothe M; Modlich U; Schambach A
Curr Gene Ther; 2013 Dec; 13(6):453-68. PubMed ID: 24195603
[TBL] [Abstract][Full Text] [Related]
5. Biosafety of onco-retroviral vectors.
VandenDriessche T; Collen D; Chuah MK
Curr Gene Ther; 2003 Dec; 3(6):501-15. PubMed ID: 14683449
[TBL] [Abstract][Full Text] [Related]
6. General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination.
Baldo A; van den Akker E; Bergmans HE; Lim F; Pauwels K
Curr Gene Ther; 2013 Dec; 13(6):385-94. PubMed ID: 24195604
[TBL] [Abstract][Full Text] [Related]
7. [Safety of retroviral vectors in gene therapy].
Bogoslovskaia EV; Glazkova DV; Shipulin GA; Pokrovskiĭ VV
Vestn Ross Akad Med Nauk; 2012; (10):55-61. PubMed ID: 23240501
[TBL] [Abstract][Full Text] [Related]
8. Retrovirus-induced oncogenesis and safety of retroviral vectors.
Nair V
Curr Opin Mol Ther; 2008 Oct; 10(5):431-8. PubMed ID: 18830918
[TBL] [Abstract][Full Text] [Related]
9. Biosafety of viral vectors commonly used in gene therapy and vaccination.
Herman P
Curr Gene Ther; 2013 Dec; 13(6):383-4. PubMed ID: 24397526
[No Abstract] [Full Text] [Related]
10. Challenges in vector and trial design using retroviral vectors for long-term gene correction in hematopoietic stem cell gene therapy.
Corrigan-Curay J; Cohen-Haguenauer O; O'Reilly M; Ross SR; Fan H; Rosenberg N; Somia N; King N; Friedmann T; Dunbar C; Aiuti A; Naldini L; Baum C; von Kalle C; Kiem HP; Montini E; Bushman F; Sorrentino BP; Carrondo M; Malech H; Gahrton G; Shapiro R; Wolff L; Rosenthal E; Jambou R; Zaia J; Kohn DB
Mol Ther; 2012 Jun; 20(6):1084-94. PubMed ID: 22652996
[No Abstract] [Full Text] [Related]
11. In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.
Bauer G; Dao MA; Case SS; Meyerrose T; Wirthlin L; Zhou P; Wang X; Herrbrich P; Arevalo J; Csik S; Skelton DC; Walker J; Pepper K; Kohn DB; Nolta JA
Mol Ther; 2008 Jul; 16(7):1308-15. PubMed ID: 18461052
[TBL] [Abstract][Full Text] [Related]
12. Retroviral gene therapy: safety issues and possible solutions.
Yi Y; Hahm SH; Lee KH
Curr Gene Ther; 2005 Feb; 5(1):25-35. PubMed ID: 15638709
[TBL] [Abstract][Full Text] [Related]
13. Environmental risk assessment of clinical trials involving modified vaccinia virus Ankara (MVA)-based vectors.
Goossens M; Pauwels K; Willemarck N; Breyer D
Curr Gene Ther; 2013 Dec; 13(6):413-20. PubMed ID: 24397528
[TBL] [Abstract][Full Text] [Related]
14. Safety concerns related to hematopoietic stem cell gene transfer using retroviral vectors.
Haviernik P; Bunting KD
Curr Gene Ther; 2004 Sep; 4(3):263-76. PubMed ID: 15384940
[TBL] [Abstract][Full Text] [Related]
15. Retroviruses as vectors.
Vile RG; Russell SJ
Br Med Bull; 1995 Jan; 51(1):12-30. PubMed ID: 7767638
[TBL] [Abstract][Full Text] [Related]
16. Development of retroviral vectors as safe, targeted gene delivery systems.
Günzburg WH; Salmons B
J Mol Med (Berl); 1996 Apr; 74(4):171-82. PubMed ID: 8740648
[TBL] [Abstract][Full Text] [Related]
17. Leukemias following retroviral transfer of multidrug resistance 1 (MDR1) are driven by combinatorial insertional mutagenesis.
Modlich U; Kustikova OS; Schmidt M; Rudolph C; Meyer J; Li Z; Kamino K; von Neuhoff N; Schlegelberger B; Kuehlcke K; Bunting KD; Schmidt S; Deichmann A; von Kalle C; Fehse B; Baum C
Blood; 2005 Jun; 105(11):4235-46. PubMed ID: 15713797
[TBL] [Abstract][Full Text] [Related]
18. Retroviral vectors: post entry events and genomic alterations.
Nowrouzi A; Glimm H; von Kalle C; Schmidt M
Viruses; 2011 May; 3(5):429-55. PubMed ID: 21994741
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
20. Retrovirus-mediated gene transfer in cancer therapy.
Uckert W; Walther W
Pharmacol Ther; 1994 Sep; 63(3):323-47. PubMed ID: 7530375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
